insight

ViewPoints Interview: Codiak BioSciences’ Douglas E. Williams Shares Insight on the Potential of its Engineered Exosomes

  • by

In an interview with PharmaShots, Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak BioSciences shares insights on the potential of engineered exosomes and the data presented at SITC 2020. Shots: Codiak demonstrated the potential of engineered exosomes –  extracellular vesicles that act… Read More »ViewPoints Interview: Codiak BioSciences’ Douglas E. Williams Shares Insight on the Potential of its Engineered Exosomes

ViewPoints Interview: Leap Therapeutic’s Douglas Onsi Shares Insight on its Lead Candidate, DKN-01

  • by

In an interview with PharmaShots, Douglas Onsi, CEO and President of Leap Therapeutics shares insights on the clinical data of DKN-01 along with its mechanism. He also highlights the company’s growth, plans, goal etc. Shots: DKK1 is a secreted protein that modulates cell signaling pathways… Read More »ViewPoints Interview: Leap Therapeutic’s Douglas Onsi Shares Insight on its Lead Candidate, DKN-01

ViewPoints Interview: Fluxergy’s Tej Patel Shares Insight on Multimodal Diagnostic System

  • by

In an interview with PharmaShots, Tej Patel, CEO of Fluxergy shared his views on Fluxergy’s CE Marking and how it will democratize healthcare while creating better clinical outcomes. Shots: Fluxergy’s One-hour COVID-19 test requires less than 2-3 minutes of hands-on time and provides lab-quality RT-PCR… Read More »ViewPoints Interview: Fluxergy’s Tej Patel Shares Insight on Multimodal Diagnostic System

ViewPoints Interview: Aravive’ s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC

  • by

In an interview with PharmaShots, Dr. Gail McIntyre, CEO of Aravive shared her views on the AVB-500, its potential against ccRCC, and the design of the clinical trial evaluating the therapy. He also shed light on epidemiology of Clear Cell Renal Cell Carcinoma. Shots: AVB-500… Read More »ViewPoints Interview: Aravive’ s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC

ViewPoints Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community

  • by

In an interview with PharmaShots, Marc Meachem, Head of US External Affairs at ViiV Healthcare shared his views on the company’s approach towards the community. He also shed light on the grants and funding received for the betterment of HIV patients. Shots: ViiV Healthcare is… Read More »ViewPoints Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community

ViewPoints Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine

  • by

In an interview with PharmaShots, Dietrich Stephan, Ph.D., CEO of NeuBase Therapeutics shared his views on the importance of preclinical in vivo data for PATrOL-enabled anti-gene for myotonic dystrophy type 1. Shots: NeuBase announced in vitro and in vivo data for its DM1 program, demonstrating… Read More »ViewPoints Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine

ViewPoints Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App

  • by

In an interview with PharmaShots, Marie Schiller Vice President of Product Development for Connected Care and Insulins at Lilly shared her views on its collaboration with Welldoc to integrate Welldoc’s insulin management technology into Lilly’s connected insulin solutions. Shots: Lilly and Welldoc are teaming up to create… Read More »ViewPoints Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App

ViewPoints Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2021

  • by

In an interview with Nirav Desai, Global Clinical Development Lead at Takeda shared his views on Tak-721 presented at ACG 2021 and its implications for patients and HCPs. The presentation includes post hoc analyses from a 12-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial that investigated the safety and… Read More »ViewPoints Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2021

ViewPoints Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment

  • by

In an interview with PharmaShots, Dr. Todd D. Cohen, M.D., VP Medical Affairs and Medical Director of Urology at Myriad Genetics shared his views on the ability of a biomarker test to predict which men with aggressive prostate cancer will benefit from advanced hormonal therapy and… Read More »ViewPoints Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment

ViewPoints Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca

  • by

In an interview with PharmaShots, John Valliant, CEO at Fusion Pharma shared his views on the company’s agreement with AstraZeneca, signed in Nov 2020. He also shared in-depth information about the company’s TATs platform & Fast-Clear linker technology and provide a glance at Fusion’s portfolio.… Read More »ViewPoints Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca

ViewPoints Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines

  • by

In an interview with PharmaShots, Lawrence Ganti, President & Chief Business Officer at SiO2 Materials Science shared his views on the efforts to scale up the manufacturing of vials to combat COVID-19. Additionally, he also shared the benefits of using SiO2’s smart vials and shed… Read More »ViewPoints Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines

ViewPoints Interview: Biogen’s Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza

  • by

In an interview with PharmaShots, Wildon R. Farwell, M.D., MPH, Global Medical Head of Neuromuscular Diseases at Biogen shared his views on the P-IV RESPOND study that assesses the benefits of Spinraza in patients treated with Zolgensma. Shots: RESPOND is a two-year, open-label study to… Read More »ViewPoints Interview: Biogen’s Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza

ViewPoints Interview: Merz Aesthetics’ Dr. Terri Phillips Shares Insight on GP Campaign for Xeomin

  • by

In an interview with PharmaShots, Dr. Terri Phillips, Chief Medical Affairs Officer at Merz Aesthetics shared her views on the new campaign with Gwyneth Paltrow for its flagship product Xeomin. She also shed light on Medical Aesthetic treatments during the pandemic and how Merz is… Read More »ViewPoints Interview: Merz Aesthetics’ Dr. Terri Phillips Shares Insight on GP Campaign for Xeomin

ViewPoints Interview: Lumen’s Brian Finrow Shares Insight on Need for the Cheaper Methods to Engineer Antibodies as a Treatment for COVID-19

  • by

In an interview with PharmaShots, Brian Finrow, Co-Founder and CEO of Lumen Bioscience shared his views on the critical need for a scalable and cheaper method to engineer antibodies as a potential treatment for Covid-19. He also shed light on why it is time for… Read More »ViewPoints Interview: Lumen’s Brian Finrow Shares Insight on Need for the Cheaper Methods to Engineer Antibodies as a Treatment for COVID-19

ViewPoints Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10)

  • by

In an interview with PharmaShots, Daniel A. de Boer of ProQR shared his views on P-II/III pivotal trial of Sepofarsen to treat the root cause of a rare eye disease, Leber congenital amaurosis 10 (LCA10) Shots: The Illuminate P-II/III trial of sepofarsen is a double-masked,… Read More »ViewPoints Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10)

ViewPoints Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on Davato (dolutegravir/lamivudine)

  • by

In an interview with PharmaShots, Dr. Kimberly Smith, Head of Research & Development, ViiV Healthcare shed light on the FDA’s approval and the 3yrs. data of Dovato. Shots: Dovato (dolutegravir/lamivudine) is the first complete, once-daily, single-tablet, 2DR for the treatment of HIV-1 infection in both… Read More »ViewPoints Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on Davato (dolutegravir/lamivudine)

ViewPoints Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel

  • by

In an interview with PharmaShots, Ying Huang, Ph.D., CEO and CFO of Legend Biotech shed light on the clinical data following the rolling submission of BLA for Cilta-cel. He also shared insight on Legends’ collaboration with Janssen. Shots: The submission of BLA was based on… Read More »ViewPoints Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel

ViewPoints Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework

  • by

In an interview with PharmaShot, Dr. Sophia Randolph, Chief Medical Officer of ALX Oncology shared her views on the ALX Oncology’s collaboration with Zymework for evaluating the combination with ALX148 and zanidatamab for patients with advanced HER2-expressing breast cancer and other HER2-expressing solid tumors. Shots:… Read More »ViewPoints Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework

ViewPoints Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020

  • by

In an interview with PharmaShots, Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera shed light on encouraging preliminary results from the ongoing P-I/II study of DCC-3014 in TGCT patients and also presented the data of QINLOCK at CTOS 2020 Shots:… Read More »ViewPoints Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020

ViewPoints Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

  • by

In an interview with PharmaShots, Bradley Galer, M.D., Chief Medical Officer at Zogenix shed light on data supporting the regulatory application and what the EU approval of Fintepla will mean in terms of reducing the high physical, emotional, and financial burden associated with the disease.… Read More »ViewPoints Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

ViewPoints Interview: Medicago’s Nathalie Landry Shares Insight on Plant-Derived Vaccine for COVID-19

  • by

In an interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago shared her views on positive results of P-I clinical trial results for its plant-derived COVID-19 vaccine.  Shots: The results of the trial demonstrated that 100% of participants developed a… Read More »ViewPoints Interview: Medicago’s Nathalie Landry Shares Insight on Plant-Derived Vaccine for COVID-19

ViewPoints Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020

  • by

In an interview with PharmaShots, Dr. Andreas Harstrick, Chief Medical Officer at Affimed shared his views on updated clinical data related to their lead innate cell engager AFM13 at the virtual 62nd American Society of Hematology (ASH) annual meeting. Shots: The study showed an ORR… Read More »ViewPoints Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020

ViewPoints Interview: Genentech’s Ted Omachi Shares Insight on the US FDA’s Approval of Xolair in Nasal polyps

  • by

In a recent interview with PharmaShots, Ted Omachi, Global Development Leader for Xolair, and Senior Medical Director of Product Development for Immunology, Genentech shared his views on the approval of Xolair in the US. Shots: The approval is based on P-III POLYP 1 & 2… Read More »ViewPoints Interview: Genentech’s Ted Omachi Shares Insight on the US FDA’s Approval of Xolair in Nasal polyps

ViewPoints Interview: ViiV Healthcare’s Kimberly Smith Shares Insight on Data of Long-Acting Cabotegravir and Rilpivirine Presented at IDWeek 2020

  • by

In a recent interview with PharmaShots, Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare shared information on the positive findings presented at the 2020 Infectious Diseases Society of America (IDWeek) and the impact of COVID-19 on the development of long-acting cabotegravir… Read More »ViewPoints Interview: ViiV Healthcare’s Kimberly Smith Shares Insight on Data of Long-Acting Cabotegravir and Rilpivirine Presented at IDWeek 2020

ViewPoints Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein Designed to Treat or Block SARS-COV-2

  • by

In a recent interview with PharmaShots Daniel-Adriano Silva, PhD, Co-founder and Vice President Head of Research at Neoleukin shared the significance and promise of the findings published in Science and discuss the details of its De Novo Protein Design Shots: NL-CVX1 (CTC-445.2d) demonstrated the ability to… Read More »ViewPoints Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein Designed to Treat or Block SARS-COV-2

ViewPoints Interview: Kezar’ Noreen Henig Shares Insight on Therapeutic Potential of KZR-616

  • by

In a recent interview with PharmaShots, Noreen Henig, Chief Medical Officer at Kezar Life Sciences shared information on clinical and pre-clinical data supporting the potential of KZR-616 to positively affect multiple drivers of immune-mediated diseases. Shots: The poster presented at ACR 2020 includes additional patient-weeks… Read More »ViewPoints Interview: Kezar’ Noreen Henig Shares Insight on Therapeutic Potential of KZR-616

ViewPoints Interview: Cellares’ Fabian Gerlighaus Shares Insight on Cell Shuttle

  • by

In a recent interview with PharmaShots, Fabian Gerlighaus, Co-Founder and CEO of Cellares, shared information on Cellares partnership with Fred Hutchinson Cancer Research Center and unveils how the company is working to get patients the cell therapies they need. Shots: Cellares’ collaboration with Fred Hutchinson… Read More »ViewPoints Interview: Cellares’ Fabian Gerlighaus Shares Insight on Cell Shuttle

ViewPoints Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma

  • by

In a recent interview with PharmaShots, William F. Doyle, Executive Chairman at Novocure shared information about the company’s activities in the field of glioblastoma and mesothelioma. He also discussed the company’s technology, Tumor Treating Fields (TTFields), and its potential for broad applicability across solid tumors.… Read More »ViewPoints Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma

ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM

  • by

In a recent interview with PharmaShots, Julie Foster, Vice President, Global Customer Experience of the Diabetes business at Medtronic, shares information about recent and upcoming announcements for the company. Shots: The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion… Read More »ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM

ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM

  • by

In a recent interview with PharmaShots, Julie Foster, Vice President, Global Customer Experience of the Diabetes business at Medtronic, shares information about recent and upcoming announcements for the company. Shots: The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion… Read More »ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM

ViewPoints Interview: Duke’s Andrea Taylor Shares Insight on Launch And Scale Speedometer

  • by

In a recent interview with PharmaShots, Andrea Taylor, Researcher at Launch And Scale Speedometer shared her insights and highlights on data how rich countries’ shopping spree for COVID-19 vaccines means fewer vaccinations for billions in low-income countries Shots: The Launch and Scale Speedometer project aims… Read More »ViewPoints Interview: Duke’s Andrea Taylor Shares Insight on Launch And Scale Speedometer

ViewPoints Interview: Caris Life Sciences’ Dr. Spetzler Shares Insight on AI-Powered Clinico-Genomic Data Platform

  • by

In a recent interview with PharmaShots, Dr. Spetzler, President and Chief Scientific Officer of Caris Life Sciences shared his insights and highlights on data of the launch of CODEai. Shots: CODEai is a real-world clinico-genomic data platform that integrates Caris Life Sciences’ extensive catalog of… Read More »ViewPoints Interview: Caris Life Sciences’ Dr. Spetzler Shares Insight on AI-Powered Clinico-Genomic Data Platform

ViewPoints Interview: True Digital Surgery’s Aidan Foley Shares Insight on Aesculap Aeos Robotic Digital Microscope

  • by

In a recent interview with PharmaShots, Aidan Foley, Chairman and Chief Operating Officer of True Digital Surgery share his insights and highlights on data of Aesculap Aeos Robotic Digital Microscope. Shots: The robotic digital microscope enables surgeons to execute precision movements in neurosurgery, spine, and… Read More »ViewPoints Interview: True Digital Surgery’s Aidan Foley Shares Insight on Aesculap Aeos Robotic Digital Microscope

ViewPoints Interview: Dicerna’s Doug Fambrough Shares Insight on Nedosiran Data Presented at ASN Week 2020

  • by

In a recent interview with PharmaShots, Doug Fambrough, Ph.D., President and CEO of Dicerna shares his insights and highlights on data of Nedosiran presented at ASN Week 2020. Shots: All participants regardless of PH subtype, achieved normal or near-normal Uox excretion @day180, 92% participants (100%… Read More »ViewPoints Interview: Dicerna’s Doug Fambrough Shares Insight on Nedosiran Data Presented at ASN Week 2020

Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team

  • by

Prescient hires three new senior members to strengthen and grow its Intelligence & Insight business LONDON, July 15, 2020—Prescient, a biopharma product and portfolio strategy partner, announces the recent appointment of three new senior members to its Intelligence & Insight business: Dr. Anuj Gupta, Rob… Read More »Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team